A Study of LY5625575 in Healthy Participants and in Participants With Inflammation (Elevated C-Reactive Protein)

The main purpose of this study is to evaluate the safety and tolerability of LY5625575 in healthy participants (including Japanese and Chinese) and in participants with high levels of a marker for inflammation (C-reactive protein). The study will also measure how much LY5625575 gets into the bloodstream and how long it takes the body to get rid of it. The study will last seven to nine weeks.

Inclusion Criteria: * All Parts: * Individuals not of childbearing potential may participate in this trial. * Individuals assigned male at birth may participate in this trial. * Healthy as defined by * the absence of clinically significant illness and surgery within 35 days prior to first dosing, and * the absence of clinically significant history of neurological, endocrine, cardiovascular, respiratory, hematological, immunological, psychiatric, gastrointestinal, renal, hepatic, and metabolic disease. * Part A: \-- Have an estimated glomerular filtration rate (eGFR), using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) creatinine equation 2021, of greater than or equal to (≥)90 milliliters per minute per 1.73 square meters (mL/min/1.73 m²) at screening. * Parts B, C, D, and E: \-- Have an eGFR, using the CKD-EPI creatinine equation 2021, of ≥60 mL/minute/1.73 m² * Parts A, B, D, and E: \-- Have a body mass index ≥18.5 and less than (\